坦索罗辛治疗慢性前列腺痛的疗效观察  

The effect observation of the tamsulosin in the chronic pelvic pain syndrome

作　　者：刘江 吴小候[2] 

机构地区：[1]重庆市巴南区安澜卫生院,401349 [2]重庆医科大学附属第一医院泌尿外科,400016

出　　处：《检验医学与临床》2011年第12期1476-1477,共2页Laboratory Medicine and Clinic

摘　　要：目的坦索罗辛(哈乐)治疗慢性前列腺痛的疗效观察。方法回顾分析在本院2008年1月至2010年1月期间接受治疗的慢性前列腺痛患者60例,随机分为治疗组和对照组。治疗组予患者患者哈乐0.2 mg qd,对照组予患者体外短波热疗。分别在治疗后3、6个月观察前列腺炎症状评分(NIH-CPSI)、峰值尿流率、残余尿(PVR)和国际勃起功能指数(IIEF)。结果坦索罗辛组在治疗后3个月,CPSI得分降低3.0±1.3,体外短波治疗组在治疗3月,CPSI得分降低1.9±0.9(P<0.05);坦索罗辛组在治疗后6个月,CPSI得分降低7.5±1.9,体外短波治疗组在治疗6个月,CPSI得分降低4.0±2.9(P<0.01)。峰值尿流率、PVR和IIEF没有明显变化。结论坦索罗辛较体外短波治疗能够明显降低慢性前列腺痛患者的前列腺炎症状评分,有效减轻患者的症状。Objective To evaluate the efficacy and long-term benefits of tamsulosin in the treatment of chronic pelvic pain syndrome.Methods A total of 60 men diagnosed with CP/CPPS were randomly allocated to receive either 0.2 mg of tamsulosin daily or etcoshortwave therapy for 6 months.Patients were followed up at 3 and 6 months after initiation of treatment.The primary outcome variable was the change from baseline in the total and domain scores of the NIH-CPSI.Secondary variables used to evaluate efficacy of treatment included the following： peak urinary flow rate,post-voiding residual（PVR） volume and the International Index of Erectile Function.Results Three months after cessation of therapy,the mean decrement of total NIH-CPSI score in two groups were 3.0±1.3 and 1.9±0.9,respectively（P 0.05）.Six months after initiation of treatment,the mean decrement of total NIH-CPSI score in tamsulosin and placebo group were 7.5±1.9 and 4.0±2.9,respectively（P 0.01）.No differences were observed for data of peak urinary flow rate,PVR and the IIEF during the research period.Conclusion Our study shows that a 6-month course of tamsulosin ameliorated symptoms of CP/CPPS more affirmatory treatment efficacy than that of etcoshortwave therapy.

关 键 词：慢性前列腺痛 坦索罗辛 体外短波治疗 疗效 

分 类 号：R697.33[医药卫生—泌尿科学]